Skip to main content
Premium Trial:

Request an Annual Quote

Mizuho Downgrades BD to Neutral

NEW YORK (GenomeWeb News) – Mizuho Securities analyst Peter Lawson today downgraded the stock of Becton Dickinson from Buy to Neutral.

Lawson noted that BD's shares, which closed at $83.94 on the New York Stock Exchange Monday, are within 4 percent of Mizuho's $87 price target. He noted that the firm's stock has risen 9 percent over the past three months and 12 percent over the past six months and no longer trades at a discount to its historical Price-t0-earnings multiple.

"We expect low single-digit organic growth for Becton over the next two years," Lawson wrote in a note published this morning. "Becton’s life science research business (BD Bioscience, approximately 15 percent of sales) has been a drag on results for the past year and we see no significant catalysts for the business in the near-term, as the academic market continues to be sluggish."

In addition to concerns over academic spending, Lawson cited growing diagnostic competition. However, he cited a potential new CFO, a realignment of the firm's R&D, and strengthened diagnostic positioning could serve as catalysts for the stock.

David Elkins, BD's former CFO, resigned last fall.

The Scan

UK Moves to Allow Sale of Gene-Edited Food

The UK is moving ahead to allow the sale of gene-edited food in England, Scotland, and Wales, according to New Scientist.

Questions for the Field

Stat News writes that the alleged Buffalo shooter's citation of genetics research raises questions about what the field can do.

Cell Studies on Tumor Evolution in Mouse Model of Lung Cancer, Stereo-seq, Bacteriophage Responses

In Cell this week: tumor evolution tracked in mouse model of lung cancer, organogenesis mapped using Stereo-seq, and more.

Taking Stock of the Stockpile

The US and European countries are evaluating their smallpox vaccine stockpiles as the number of monkeypox cases increases, the Washington Post reports.